DOI QR코드

DOI QR Code

Comprehensive Assessment of Associations between ERCC2 Lys751Gln/Asp312Asn Polymorphisms and Risk of Non-Hodgkin Lymphoma

  • Zhou, Jue-Yu (Institute of Genetic Engineering, Southern Medical University) ;
  • He, Li-Wen (Institute of Genetic Engineering, Southern Medical University) ;
  • Liu, Jie (Department of Gynaecology and Obstetrics, Nanfang Hospital, Southern Medical University) ;
  • Yu, Hai-Lang (Institute of Genetic Engineering, Southern Medical University) ;
  • Wei, Min (Institute of Genetic Engineering, Southern Medical University) ;
  • Ma, Wen-Li (Institute of Genetic Engineering, Southern Medical University) ;
  • Shi, Rong (Institute of Genetic Engineering, Southern Medical University)
  • Published : 2014.11.28

Abstract

Background: Excision repair crossing-complementing group 2 (ERCC2), also called xeroderma pigmentosum complementary group D (XPD), plays a crucial role in the nucleotide excision repair (NER) pathway. Previous epidemiological studies have reported associations between ERCC2 polymorphisms and non-Hodgkin lymphoma (NHL) risk, but the results have remained controversial. Materials and Methods: We conducted this meta-analysis based on eligible case-control studies to investigate the role of two ERCC2 polymorphisms (Lys751Gln and Asp312Asn) in determining susceptibility to NHL. Ten case-control studies from several electronic databases were included in our study up to August 14, 2014. Pooled odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using fixed- or random-effects models to estimate the association strength. Results: The combined results based on all studies did not show any association between Lys751Gln/Asp312Asn polymorphisms and NHL risk for all genetic models. Stratified analyses by histological subtype and ethnicity did not indicate any significant association between Lys751Gln polymorphism and NHL risk. However, a significant reduced risk of NHL was found among population-based studies (Lys/Gln versus Lys/Lys: OR=0.87, 95% CI=0.77-0.99, P=0.037) but not hospital-based studies. As for Asp312Asn polymorphism, there was no evidence for the association between this polymorphism and the risk of NHL in all subgroup analyses. Conclusions: This meta-analysis suggests that there may be no association between Lys751Gln/Asp312Asn polymorphism and the risk of NHL and its two subtypes, whereas ERCC2 Lys751Gln heterozygote genotype may provide protective effects against the risk of NHL in population-based studies. Therefore, large-scale and well-designed studies are needed to clarify the effects of haplotypes, gene-gene, and gene-environment interactions on these polymorphisms and the risk of NHL and its different histological subtypes in an ethnicity specific population.

Acknowledgement

Supported by : Science and Technology in Guangzhou

References

  1. Berwick M, Vineis P (2000). Markers of DNA repair and susceptibility to cancer in humans: an epidemiologic review. J Natl Cancer Inst, 92, 874-97. https://doi.org/10.1093/jnci/92.11.874
  2. Chiu BC, Weisenburger DD, Zahm SH, et al (2004). Agricultural pesticide use, familial cancer, and risk of non-Hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev, 13, 525-31.
  3. Cochran W (1954). The combination of estimates from different experiments. Biometrics, 10, 101-29. https://doi.org/10.2307/3001666
  4. de Boer J, Hoeijmakers JH (2000). Nucleotide excision repair and human syndromes. Carcinogenesis, 21, 453-60. https://doi.org/10.1093/carcin/21.3.453
  5. De Silva IU, McHugh PJ, Clingen PH, et al (2000). Defining the roles of nucleotide excision repair and recombination in the repair of DNA interstrand cross-links in mammalian cells. Mol Cell Biol, 20, 7980-90. https://doi.org/10.1128/MCB.20.21.7980-7990.2000
  6. DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88. https://doi.org/10.1016/0197-2456(86)90046-2
  7. Duan XL, Gong H, Zeng XT, et al (2012). Association between XPD Asp312Asn polymorphism and esophageal cancer susceptibility: a meta-analysis. Asian Pac J Cancer Prev, 13, 3299-303. https://doi.org/10.7314/APJCP.2012.13.7.3299
  8. Egger M, Davey Smith G, Schneider M, et al (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ, 315, 629-34. https://doi.org/10.1136/bmj.315.7109.629
  9. El-Din MA, Khorshied MM, El-Saadany ZA, et al (2013). Excision repair cross-complementing group 2/Xeroderma pigmentousm complementation group D (ERCC2/XPD) genetic variations and susceptibility to diffuse large B cell lymphoma in Egypt. Int J Hematol, 98, 681-6. https://doi.org/10.1007/s12185-013-1462-1
  10. Evans E, Moggs JG, Hwang JR, et al (1997). Mechanism of open complex and dual incision formation by human nucleotide excision repair factors. EMBO J, 16, 6559-73. https://doi.org/10.1093/emboj/16.21.6559
  11. Fabisiewicz A, Pacholewicz K, Paszkiewicz-Kozik E, et al (2013). Polymorphisms of DNA repair and oxidative stress genes in B-cell lymphoma patients. Biomed Rep, 1, 151-5.
  12. Baris S, Celkan T, Batar B, et al (2009). Association between genetic polymorphism in DNA repair genes and risk of B-cell lymphoma. Pediatr Hematol Oncol, 26, 467-72. https://doi.org/10.3109/08880010903096201
  13. Benhamou S, Sarasin A (2002). ERCC2/XPD gene polymorphisms and cancer risk. Mutagenesis, 17, 463-9. https://doi.org/10.1093/mutage/17.6.463
  14. Friedberg EC (2001). How nucleotide excision repair protects against cancer. Nat Rev Cancer, 1, 22-33. https://doi.org/10.1038/35094000
  15. Gillet LC, Scharer OD (2006). Molecular mechanisms of mammalian global genome nucleotide excision repair. Chem Rev, 106, 253-76. https://doi.org/10.1021/cr040483f
  16. Grulich AE, Vajdic CM, Cozen W (2007). Altered immunity as a risk factor for non-Hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev, 16, 405-8. https://doi.org/10.1158/1055-9965.EPI-06-1070
  17. Hartge PWS (2004). Overview of the etiology and epidemiology of lymphoma. In: Mauch PM, Armitage JO, Coiffier B, et al. (eds). Non-Hodgkin's Lymphomas. Lippincott Williams and Wilkins, New York, NY, pp711-27.
  18. Higgins JP, Thompson SG, Deeks JJ, et al (2003). Measuring inconsistency in meta-analyses. BMJ, 327, 557-60. https://doi.org/10.1136/bmj.327.7414.557
  19. Huang LM, Shi X, Yan DF, et al (2014). Association between ERCC2 polymorphisms and glioma risk: a meta-analysis. Asian Pac J Cancer Prev, 15, 4417-22. https://doi.org/10.7314/APJCP.2014.15.11.4417
  20. Itin PH, Sarasin A, Pittelkow MR (2001). Trichothiodystrophy: update on the sulfur-deficient brittle hair syndromes. J Am Acad Dermatol, 44, 891-920. https://doi.org/10.1067/mjd.2001.114294
  21. Kim HN, Kim NY, Yu L, et al (2014). Polymorphisms in DNA repair genes and MDR1 and the risk for non-Hodgkin lymphoma. Int J Mol Sci, 15, 6703-16. https://doi.org/10.3390/ijms15046703
  22. Li SX, Dai QS, Chen SX, et al (2014). Xeroderma pigmentosum complementation group D (XPD) gene polymorphisms contribute to bladder cancer risk: a meta-analysis. Tumour Biol, 35, 3905-15. https://doi.org/10.1007/s13277-013-1519-z
  23. Liu D, Wu D, Li H, et al (2014). The effect of XPD/ERCC2 Lys751Gln polymorphism on acute leukemia risk: a systematic review and meta-analysis. Gene, 538, 209-16. https://doi.org/10.1016/j.gene.2014.01.049
  24. Lunn RM, Helzlsouer KJ, Parshad R, et al (2000). XPD polymorphisms: effects on DNA repair proficiency. Carcinogenesis, 21, 551-5. https://doi.org/10.1093/carcin/21.4.551
  25. Mantel N, Haenszel W (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst, 22, 719-48.
  26. Shen M, Purdue MP, Kricker A, et al (2007). Polymorphisms in DNA repair genes and risk of non-Hodgkin's lymphoma in New South Wales, Australia. Haematologica, 92, 1180-5. https://doi.org/10.3324/haematol.11324
  27. Shen M, Zheng T, Lan Q, et al (2006). Polymorphisms in DNA repair genes and risk of non-Hodgkin lymphoma among women in Connecticut. Hum Genet, 119, 659-68. https://doi.org/10.1007/s00439-006-0177-2
  28. Smedby KE, Lindgren CM, Hjalgrim H, et al (2006). Variation in DNA repair genes ERCC2, XRCC1, and XRCC3 and risk of follicular lymphoma. Cancer Epidemiol Biomarkers Prev, 15, 258-65. https://doi.org/10.1158/1055-9965.EPI-05-0583
  29. Song B, Zhu JY, Liu J, et al (2008). Association of gene polymorphisms in the DNA repair gene XPD with risk of non-Hodgkin's lymphoma. Zhongguo Shi Yan Xue Ye Xue Za Zhi, 16, 97-100 (in Chinese).
  30. Sung P, Bailly V, Weber C, et al (1993). Human xeroderma pigmentosum group D gene encodes a DNA helicase. Nature, 365, 852-5. https://doi.org/10.1038/365852a0
  31. Weber CA, Salazar EP, Stewart SA, et al (1990). ERCC2: cDNA cloning and molecular characterization of a human nucleotide excision repair gene with high homology to yeast RAD3. Embo j, 9, 1437-47.
  32. Wood RD, Mitchell M, Sgouros J, et al (2001). Human DNA repair genes. Science, 291, 1284-9. https://doi.org/10.1126/science.1056154
  33. Worrillow L, Roman E, Adamson PJ, et al (2009). Polymorphisms in the nucleotide excision repair gene ERCC2/XPD and risk of non-Hodgkin lymphoma. Cancer Epidemiol, 33, 257-60. https://doi.org/10.1016/j.canep.2009.08.002
  34. Xin Y, Hao S, Lu J, et al (2014). Association of ERCC1 C8092A and ERCC2 Lys751Gln polymorphisms with the risk of glioma: a meta-analysis. PLoS One, 9, 95966. https://doi.org/10.1371/journal.pone.0095966
  35. Yan Y, Liang H, Light M, et al (2014). XPD Asp312Asn and Lys751Gln polymorphisms and breast cancer susceptibility: a meta-analysis. Tumour Biol, 35, 1907-15. https://doi.org/10.1007/s13277-013-1256-3
  36. Yang F, Shi JY, Xu L, et al (2009). Genetic susceptibility of single nucleotide polymorphism in MGMT to non-Hodgkin lymphoma. Zhonghua Xue Ye Xue Za Zhi, 30, 622-5 (in Chinese).
  37. Yin QH, Liu C, Hu JB, et al (2013). XPD Lys751Gln and Asp312Asn polymorphisms and gastric cancer susceptibility: a meta-analysis of case-control studies. Asian Pac J Cancer Prev, 14, 231-6. https://doi.org/10.7314/APJCP.2013.14.1.231
  38. Zhu HL, Bao JM, Lin PX, et al (2014). XPD Lys751Gln and Asp312Asn polymorphisms and susceptibility to skin cancer: a meta-analysis of 17 case-control studies. Asian Pac J Cancer Prev, 15, 6619-25. https://doi.org/10.7314/APJCP.2014.15.16.6619

Cited by

  1. Adult Non Hodgkin's Lymphoma Patients: Experience from a Tertiary Care Cancer Centre in North East India vol.16, pp.7, 2015, https://doi.org/10.7314/APJCP.2015.16.7.2879